Entries by Katja Buhrer

Kindred Biosciences Announces Pricing of Public Offering

SAN FRANCISCO, California. (January 18, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount […]

Kindred Biosciences Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, California. (January 17, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. All of the common stock is being offered by KindredBio. In addition, KindredBio intends to grant the underwriters a […]

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital

SAN FRANCISCO, CA (January 14, 2019) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness study of epoCat (KIND-510a), a long-acting feline recombinant erythropoietin that is being developed for the management of anemia in cats. In […]

Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

SAN FRANCISCO, September 17, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Cantor Global Healthcare Conference on October 1 and the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 in New York City. Denise Bevers, Co-Founder and Chief Operating Officer, will […]

Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit

SAN FRANCISCO, August 30, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the LD Micro San Francisco Summit taking place September 4th, the CL King 16th Annual Best Ideas Conference and the Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference, both […]